Technology | Radiation Therapy | September 13, 2019

Akesis Galaxy SRS System Receives FDA 510(k) Clearance

Gamma stereotactic radiosurgery system offers continuous 360-degree rotation for high-precision intracranial treatments

Akesis Galaxy SRS System Receives FDA 510(k) Clearance

September 13, 2019 — The Akesis Galaxy, a gamma stereotactic radiosurgery (SRS) system with continuous 360-degree rotational technology, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), making the system available to clinicians in the United States.

For patients, the Akesis Galaxy offers efficient delivery of high-precision intracranial treatments thanks to the patented, continuous 360-degree rotational technology. The system offers a large choice of automated collimator selections to build more complex composite shots, “shrink-wrapping” the dose distribution to the target. With only 30 gamma sources, the Galaxy lowers the total cost of ownership and reduces downtime during source replacement.

The Akesis Galaxy builds on isometric design principles that have been published in more than 2,000 peer-reviewed papers for Co-60 based radiosurgery. With < 0.5mm radiologic accuracy, Akesis Galaxy also provides sharp dose fall-off, with potentially better sparing of organs at risk.

The system is an ideal solution for high-throughput institutions, smaller cancer centers and value-based reimbursement models.

The Akesis Galaxy will be on display at the American Society for Radiation Oncology (ASTRO) 2019 annual meeting, Sept. 15-18 in Chicago.

For more information: www.akesis.com

Related Content

Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
News | Clinical Trials | February 03, 2020
February 3, 2020 — Melding the genetic and cellular analysis of tumors with how they appear in medical images could g
Elekta Unity MR Linac system
News | Radiation Oncology | January 30, 2020
January 30, 2020 — Elekta announced that it signed a contract wit